DGAP-News: 4SC Receives EU Grant to Identify New Drugs for the Treatment of Rheumatoid Arthritis as Part of a Consortium
(firmenpresse) - DGAP-News: 4SC AG / Key word(s): Miscellaneous
4SC Receives EU Grant to Identify New Drugs for the Treatment of
Rheumatoid Arthritis as Part of a Consortium
22.12.2010 / 07:30
---------------------------------------------------------------------
Planegg-Martinsried, Germany - 22 December, 2010 - 4SC AG (Frankfurt, Prime
Standard: VSC), today announced that the European Union has supported a
research consortium, by awarding a EUR5.8 million grant, in order to
unravel the link between periodontal disease and rheumatoid arthritis (RA)
in order to identify potential novel drugs against RA.
RA is chronic inflammatory joint disease that afflicts 0.5 - 1% of the
World's population. In the late stage of the disease irreversible damage to
joint cartilage and bones occurs. Causes of this disease are genetic but
can also be based on autoimmune factors. Mounting evidence suggests that
autoimmunity can be triggered by infectious agents such as those
responsible for periodontal disease. The project proposes to unravel the
mechanistic links between these two diseases. 4SC will investigate the role
of cytokines like Interleukin 17 (IL-17) in this context and plans to
identify selective low molecular weight inhibitors of enzymes responsible
for triggering the autoimmune reactions leading to RA. The successful
identification of new inhibitors will enable the development of a new
generation of drugs that may have the potential to prevent and treat RA in
early stages after disease onset.
The project is being co-ordinated by Dr. Peter Mydel from the University of
Gothenburg, Sweden. In addition to 4SC, the second commercial partner is
Anaxomics Biotech, Spain. A large number of scientific institutions are
participating in the project, including: the University of Gothenburg,
Sweden; Jagiellonian University, Krakow, Poland; University of Aarhus,
Denmark; Karolinska Institute, Stockholm, Sweden; Molecular Biology
Institute of Barcelona (IBMB-CSIC), Spain; University of Birmingham, UK;
University of Glasgow, UK; Kennedy Institute of Rheumatology, London, UK;
and University of Florence, Italy.
Daniel Vitt, Chief Scientific Officer, commented 'This research grant
supports our internal activities and drug discovery efforts in an
indication area that is a key focus of 4SC. Our research objective is to
identify innovative and novel approaches that may help to create leading
drugs in the future, based on unmet medical need and commercial
opportunity. We look forward to working with such a prestigious consortium
in order to assess the potential of the link between autoimmune factors and
rheumatoid arthritis.'
-Ends-
About 4SC
4SC AG (ISIN DE0005753818) is a drug discovery and development company
focused on autoimmune and cancer indications. Vidofludimus (4SC-101), a
small molecule, is currently in Phase II development in rheumatoid
arthritis and inflammatory bowel disease (IBD), for which positive results
from a Phase IIa study were recently reported. The company's lead oncology
compound, resminostat (4SC-201), a pan-histone deacetylase (HDAC)
inhibitor, is in Phase II trials in hepatocellular carcinoma and Hodgkin's
lymphoma. Two further oncology compounds, 4SC-203 and 4SC-205, are in Phase
I studies. 4SC develops drug candidates until proof-of-concept in order to
generate value creating partnerships with the pharmaceutical industry in
return for advance and milestone payments as well as royalties.
Founded in 1997, 4SC has 94 employees and has been listed on the Prime
Standard of the Frankfurt Stock Exchange since December 2005.
For further information, please visit www.4sc.com.
Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.
For more information please contact:
4SC AG
Yvonne Alexander
Investor&Public Relations
Tel.: +49 (0) 89 70 07 63 66
MC Services (Europe)
Raimund Gabriel
Tel.: +49 (0) 89 21 02 28 40
The Trout Group (USA)
Chad Rubin
Tel.: +1 646 378 2947
End of Corporate News
22.12.2010 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Deutschland
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public(at)4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
107246 22.12.2010
Datum: 22.12.2010 - 07:30 Uhr
Sprache: Deutsch
News-ID 32915
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 456 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: 4SC Receives EU Grant to Identify New Drugs for the Treatment of Rheumatoid Arthritis as Part of a Consortium"
steht unter der journalistisch-redaktionellen Verantwortung von
4SC AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
